about
Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding.Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1.Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants.Impaired fibrinolytic capacity and early recurrent spontaneous abortionThe evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities.Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study.Prevalence of HFE mutations in people from North Africa living in southern France.Rare coagulation disorders: fibrinogen, factor VII and factor XIII.Rapid detection of beta-Thalassemia alleles in Egypt using naturally or amplified created restriction sites and direct sequencing: a step in disease control.European retrospective study of real-life haemophilia treatment.Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015.SULFs in human neoplasia: implication as progression and prognosis factors.Circulating FVIII-specific IgG, IgA and IgM memory B cells from haemophilia A patients.Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.HAMP promoter mutation nc.-153C>T in non p.C282Y homozygous patients with iron overload.[Deep venous thrombosis complications during infections in pediatric patients: analysis of a series of 24 cases].[Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants?].Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis.Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury.Chemical vs. radioactive synoviorthesis for treatment of chronic haemophilic synovitis: Syrian experience.A Haut-Doubs FVII variant depending on species-derived-thromboplastin reagent (F7:p.Arg337His).Direct carrier detection for severe haemophilia A: application to families with no available affected male.Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?Computer-predicted peptides that mimic discontinuous epitopes on the A2 domain of factor VIII.PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.Short-term and mid-term outcome of total ankle replacement in haemophilic patients.Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date.Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology.Genotype and phenotype relationships in 10 Pakistani unrelated patients with inherited factor VII deficiency.[The concept of aspirin "resistance": mechanisms and clinical relevance].A new high affinity variant Hb Aurillac (β141Leu→Val).Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.No significant association between CYP1A2 polymorphism and porphyria cutanea tarda.
P50
Q30683051-1AE3D76E-12DC-405D-B348-CA43E8E0656DQ33340362-E481D753-8071-4A3E-90B4-A81FA4975BA7Q33772964-064D1782-856C-45C1-A134-73AFA9F33292Q34750501-1C0988F1-91D8-4F4B-A3CB-F537C14C1801Q35169528-0821C65C-6DEB-4C07-A5A3-1870A3A15050Q36103131-CD4A7B10-C1D9-49BB-8F97-DA8E0882BECFQ36862474-15EA5CB0-9629-41C0-9EDF-C12F04CB610CQ37378510-5F098F18-3C50-4FB8-962E-6B8871D90D3FQ38471154-FC753ADD-E540-4076-890D-0B4523A3161EQ38862702-B45024B1-537A-4F9E-BDE7-47EFEA4FCADAQ38894164-D045574B-141F-4C74-B34E-84701F54E2EBQ39089443-B870F9C8-53AC-4293-A966-337BA6338114Q39268322-26B861B3-33C5-4777-B54C-F932FD87B852Q39359988-65AAED91-8760-41AF-8F0C-2A9B16E2C79DQ39390171-00CB5E7C-EA1B-40CD-BF35-D2149E72848BQ39579399-5140F3BC-23B3-477F-97BF-DF4FABB85FB0Q39593419-1D09939E-8CA5-4847-9728-B63786E3BE18Q39659820-82DC9321-4699-4123-9404-7A542CAFEA3AQ42745366-6FEA0AD3-AFF3-4135-B7A4-A7BB13D57BA9Q44047441-1D69B54A-51DC-4525-91F1-F9450555365DQ44154008-D2EA753D-1F2E-4B40-A632-0F2A24D55AD5Q44906223-00255DB6-BC7F-4B23-9C6E-BE7503A4001EQ44988512-69699034-BA5F-4D04-8751-E8F7A6C75DB8Q45862023-2BE25545-ED6C-41E4-82B3-02156CC962D5Q45864916-C7914DD3-CB7F-4367-95EC-0C258DD05F3FQ45866601-1C8DCAE0-3171-4792-A870-B14D2FDC5943Q45869344-96130CCD-6F39-4B1B-869A-52CE4838A65DQ45870411-1AE8C4F0-E4C1-440F-B219-7C0A8808FECEQ45870435-D6E99C12-6E4E-4B4F-8C20-63E13E5192E6Q45870805-1197DB6C-EDEF-4044-9EEF-B90C0DBF443CQ45872212-F65B61AF-B90F-42E2-BD2B-0ED18AE77061Q45875415-1BBE4CA7-C491-498F-9158-6072F38AA31CQ45877007-EBFA2B40-9C5B-45C3-BC8F-70F365CBCC39Q45880409-DFACC24F-7470-4CE6-9E61-932973257EC9Q45883965-D386A946-441D-4560-AE05-483060EC9872Q45888005-6601F207-0DF3-40F0-B2B7-F6DCCD6F6556Q45930919-EE4F3AD1-9AA0-4DBA-9E0E-32557A498266Q46147483-6E27ED3C-95B8-4087-A029-0BAF80F7001CQ46317170-014904CB-F298-4464-9BDD-6CD69B1A47CFQ47329380-EEB077E2-7BFA-4EEB-93EA-4862BDF84DDB
P50
description
researcher ORCID ID = 0000-0003-0332-3254
@en
wetenschapper
@nl
name
Jean-Francois Schved
@ast
Jean-Francois Schved
@en
Jean-Francois Schved
@es
Jean-Francois Schved
@nl
type
label
Jean-Francois Schved
@ast
Jean-Francois Schved
@en
Jean-Francois Schved
@es
Jean-Francois Schved
@nl
prefLabel
Jean-Francois Schved
@ast
Jean-Francois Schved
@en
Jean-Francois Schved
@es
Jean-Francois Schved
@nl
P106
P31
P496
0000-0003-0332-3254